Sign inSubscribe

target directory

6 bemotrizinol bemt clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT05254925
Source recordAI-normalized

Evaluation of Topically Applied Bemotrizinol for Human Phototoxic Potential

This clinical trial evaluated the phototoxic potential of 6% Bemotrizinol in various formulations compared to vehicle controls. Conducted by dsm-firmenich Switzerland AG, the study aimed to assess safety and efficacy in human subjects, focusing on skin reactions post-UV exposure.

AI analysis

Indication: Phototoxic Response

Modality: small molecule

Target: 6% Bemotrizinol (BEMT)

Sponsor: dsm-firmenich Switzerland AG

Source URL: ClinicalTrials.gov

Source updated: Aug 26, 2022

Ingested: May 30, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: 6% Bemotrizinol (BEMT)

View original source fields

Condition raw: Phototoxic Response

Condition normalized: Phototoxic Response

Modality raw: Phototoxic Response

Modality normalized: small molecule

Target raw: 6% Bemotrizinol (BEMT)

Target normalized: 6% Bemotrizinol (BEMT)

Open report